COMBAT Medical is committed to investing in research and development, clinical trials and real world evidence based studies. Demonstrating the effectiveness of Combat’s patented technology and creating a solid foundation for its use.
Please click a category below to view the abstracts
HIVEC in High Risk NMIBC
BCG vs Chemohyperthermia with Mitomycin C for High-Risk Non-Muscle Invasive Bladder Carcinoma: Preliminary Results of HIVEC-HR Randomised Clinical Trial. 2019 and 2020
ABSTRACT: https://www.auajournals.org/doi/abs/10.1097/JU.0000000000000823.01 PDF: https://www.auajournals.org/doi/pdf/10.1097/JU.0000000000000823.01
Chemohyperthermia with Mitomycin C (MMC) and COMBAT System in High Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC): A New Alternative? ABSTRACT: https://www.auajournals.org/doi/10.1016/j.juro.2018.02.2757 PDF: https://www.auajournals.org/doi/pdf/10.1016/j.juro.2018.02.2757
Chemohyperthermia with Mitomycin C and COMBAT System in High Risk Non-Muscle Invasive Bladder Cancer Patients: Initial Experience in a Single Centre https://abstracts.mirrorsmed.org/abstracts/chemohyperthermia-mitomycin-c-and-combat-system-high-risk-non-muscle-invasive-bladder
ABSTRACT: https://www.auajournals.org/doi/abs/10.1097/JU.0000000000000823.01 PDF: https://www.auajournals.org/doi/pdf/10.1097/JU.0000000000000823.01
Chemohyperthermia with Mitomycin C (MMC) and COMBAT System in High Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC): A New Alternative? ABSTRACT: https://www.auajournals.org/doi/10.1016/j.juro.2018.02.2757 PDF: https://www.auajournals.org/doi/pdf/10.1016/j.juro.2018.02.2757
Chemohyperthermia with Mitomycin C and COMBAT System in High Risk Non-Muscle Invasive Bladder Cancer Patients: Initial Experience in a Single Centre https://abstracts.mirrorsmed.org/abstracts/chemohyperthermia-mitomycin-c-and-combat-system-high-risk-non-muscle-invasive-bladder
HIVEC in BCG Failure & BCG Unresponsive
Intravesical Chemohyperthermia (HIVEC) in BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients: Oncological Outcomes of a Multi-Centre European Registry
EAU Resource Centre | EAU20V (uroweb.org) (need to login in order to view)
Or
https://www.researchgate.net/publication/343009316_Intravesical_chemohyperthermia_HIVEC-E_in_BCG_unresponsive_non-muscle_invasive_bladder_cancer_patients_Oncological_outcomes_of_a_multi-centre_European_registry (need to download full text PDF)
Hyperthermic Intravesical Chemotherapy for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Patients
Abstract
https://www.auajournals.org/doi/full/10.1016/j.juro.2018.02.3007
& PDF
https://www.auajournals.org/doi/pdf/10.1016/j.juro.2018.02.3007
Heat Targeted Drug Delivery (COMBAT) in Superficial TCC: First Midterm Results in a Cohort of High-Risk Patients Scheduled for Cystectomy
https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.6_suppl.442
HIVEC in Neo-Adjuvant Setting
Chemo-Resection with Hyperthermic Intravesical Instillation (HIVEC-R) Vs Standard Treatment in Patients With Intermediate-High Risk Nmibc: Comparative, Prospective, Randomized, Controled Study of Efficacy and Tolerability: Preliminary Results
Abstract MP73-06 CHEMO-RESECTION WITH HYPERTHERMIC INTRAVESICAL INSTILLATION (HIVEC-R) VS STANDARD TREATMENT IN PATIENTS WITH INTERMEDIATE-HIGH RISK NMIBC: COMPARATIVE, PROSPECTIVE, RANDOMIZED, CONTROLED STUDY OF EFFICACY AND TOLERABILITY: PRELIMINARY RESULTS | Journal of Urology (auajournals.org) & PDF MP73-06 CHEMO-RESECTION WITH HYPERTHERMIC INTRAVESICAL INSTILLATION (HIVEC-R) VS STANDARD TREATMENT IN PATIENTS WITH INTERMEDIATE-HIGH RISK NMIBC: COMPARATIVE, PROSPECTIVE, RANDOMIZED, CONTROLED STUDY OF EFFICACY AND TOLERABILITY: PRELIMINARY RESULTS (auajournals.org)
The Reduction of the Neutrophil / Lymphocyte Ratio (NLR) is Associated with a Complete Response and Disease-Free Survival in Patients with Non-Muscle Invasive Bladder Cancer Treated with Intravesical Neoadjuvant Chemohyperthermia
Poster presentation at https://www.aeu.es/aplicaciones/presentaciones/guo2019.aspx#
Abstract MP73-06 CHEMO-RESECTION WITH HYPERTHERMIC INTRAVESICAL INSTILLATION (HIVEC-R) VS STANDARD TREATMENT IN PATIENTS WITH INTERMEDIATE-HIGH RISK NMIBC: COMPARATIVE, PROSPECTIVE, RANDOMIZED, CONTROLED STUDY OF EFFICACY AND TOLERABILITY: PRELIMINARY RESULTS | Journal of Urology (auajournals.org) & PDF MP73-06 CHEMO-RESECTION WITH HYPERTHERMIC INTRAVESICAL INSTILLATION (HIVEC-R) VS STANDARD TREATMENT IN PATIENTS WITH INTERMEDIATE-HIGH RISK NMIBC: COMPARATIVE, PROSPECTIVE, RANDOMIZED, CONTROLED STUDY OF EFFICACY AND TOLERABILITY: PRELIMINARY RESULTS (auajournals.org)
The Reduction of the Neutrophil / Lymphocyte Ratio (NLR) is Associated with a Complete Response and Disease-Free Survival in Patients with Non-Muscle Invasive Bladder Cancer Treated with Intravesical Neoadjuvant Chemohyperthermia
Poster presentation at https://www.aeu.es/aplicaciones/presentaciones/guo2019.aspx#
HIVEC in Perioperative
Prospective Randomised Clinical Trial of Chemo-hyperthermia with Mitomycin-C Prior to Transurethral Resection of the Bladder and its Relationship with the Rate of Early Recurrence in Non-Muscle Invasive Bladder Cancer: Intermediate Analysis
Abstract: https://www.auajournals.org/doi/abs/10.1097/JU.0000000000000922.12 PDF: https://www.auajournals.org/doi/pdf/10.1097/JU.0000000000000922.12
Abstract: https://www.auajournals.org/doi/abs/10.1097/JU.0000000000000922.12 PDF: https://www.auajournals.org/doi/pdf/10.1097/JU.0000000000000922.12
HIVEC in High Risk in a Sequential Therapy Regime with BCG
One Year Follow up Results After Sequential Intravesical Bacillus Calmette-Guérin and Device Assisted Chemo-Hyperthermia (Mitomycin C Delivered by The COMBAT BRS System) for High Risk Non-Muscle Invasive Bladder Cancer Patients… A Bacillus Calmette-Guérin Sparing Strategy
https://university.auanet.org/abstract_detail.cfm?id=PD19-07&meetingID=17BOS
HIVEC in Intermediate - High Risk NMIBC
HIVEC® in Intermediate – High Risk Non-Muscle Invasive Bladder Cancer
https://www.tandfonline.com/doi/full/10.3109/02656736.2016.1142618
Safety & Tolerability & Quality of Life
Safety and Tolerability Analysis of Hyperthermic Intravesical Mitomycin to Mitomycin alone in HIVEC I and HIVEC II: An Interim Analysis of 307 Patients
https://www.researchgate.net/publication/315589552_Safety_and_tolerability_analysis_of_hyperthermic_intravesical_mitomycin_to_mitomycin_alone_in_HIVEC_I_and_HIVEC_II_An_interim_analysis_of_307_patients
Quality of Life (QoL), Non Muscle Invasive Bladder Cancer (NMIBC) and Endovesical Treatments: Installation Matters https://abstracts.mirrorsmed.org/abstracts/quality-life-qol-non-muscle-invasive-bladder-cancer-nmibc-and-endovesical-treatments
Quality of Life (QoL), Non Muscle Invasive Bladder Cancer (NMIBC) and Endovesical Treatments: Installation Matters https://abstracts.mirrorsmed.org/abstracts/quality-life-qol-non-muscle-invasive-bladder-cancer-nmibc-and-endovesical-treatments
Hyperthermia Mode of Action
To Register for Clinical Updates